market folly

Jeff Ubben's activist investment firm ValueAct Capital has filed an amended 13D with the SEC regarding its position in Bioverativ (BIVV).  Per the filing, ValueAct now owns 3.8% of the company with just over 4 million shares.

This is a decrease from the previous 8.4 million shares that they previously owned at the end of the first quarter of 2017.  The latest filing shows ValueAct sold over 4.68 million shares from June 19th through July 13th at prices ranging from $59.70 to $62.56.

We've also highlighted another stock ValueAct has been selling here.

Per Google Finance, Bioverativ is "a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively. ELOCTATE and ALPROLIX use a process known as Fc fusion to link recombinant factor VIII and factor IX, respectively, to a protein fragment in the body known as Fc. The fusion of the factor with the Fc protein fragment uses a naturally occurring pathway and is designed to extend the half-life of the factor thereby making the product last longer in a person's blood than various factor therapies. Its pipeline includes BIVV 001(rFVIIIFc-VWF-XTEN) and BIVV 002 (rFIXFc-XTEN)."